GSK to seek dismissal of Zantac Florida case as court rejects testimony

(Sharecast News) - UK pharma giant GSK has welcomed a US court ruling excluding expert testimony in the long-running Zantac lawsuit where the plaintiffs allege the heartburn drug caused cancer and said it would now ask for the case to be dismissed. GSK said it would now seek dismissal of the upcoming Wilson case in the Florida State Court where the plaintiffs "alleged a causal link between ranitidine and prostate cancer".

In 2020, the US Food and Drug Administration (FDA) asked drugmakers to pull Zantac, also known as ranitidine, off the market over concerns it could turn into a cancer-causing chemical when exposed to heat.

The company this week won a case, breaking a run of settlement with claimants. GSK and other firms who have distributed the drug, Pfizer and Sanofi, face lawsuits from thousands of people with cancer related claims.

Reporting by Frank Prenesti for Sharecast.com